ImmunoPrecise Antibodies (IPA) has developed a new class of GLP-1 therapies entirely through artificial intelligence, designed to enhance efficacy, safety, therapy longevity, and patient satisfaction ...
Jennifer Bath, CEO of ImmunoPrecise Antibodies. "These patterns, which only IPA possesses, are the key to unlocking unprecedented speed and precision in biologics research. LENS ai is not just ...
ImmunoPrecise Antibodies Ltd. (IPA ... and patient satisfaction in diabetes treatment. These AI-designed therapeutics aim to improve upon current GLP-1 therapies, which are widely used for ...